• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向炎症性肠病的益生菌疗法:疾病管理进展与机遇的最新情况

PROBIOTIC APPROACHES FOR TARGETING INFLAMMATORY BOWEL DISEASE: AN UPDATE ON ADVANCES AND OPPORTUNITIES IN MANAGING THE DISEASE.

作者信息

Kumar Manoj, Hemalatha Rajkumar, Nagpal Ravinder, Singh Birbal, Parasannanavar Devraj, Verma Vinod, Kumar Ashok, Marotta Francesco, Catanzaro Roberto, Cuffari Biagio, Jain Shalini, Bissi Laura, Yadav Hariom

机构信息

Department of Microbiology and Immunology, National Institute of Nutrition, Hyderabad.

Probiotics Research Laboratory, Graduate School of Medicine, Juntendo University, Tokyo.

出版信息

Int J Probiotics Prebiotics. 2016;11(3-4):99-116.

PMID:31452650
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6709984/
Abstract

Various commensal enteric and pathogenic bacteria may be involved in the pathogenesis of inflammatory bowel diseases (IBDs), a chronic condition with a pathogenic background that involves both immunogenetic and environmental factors. IBDs comprising of Crohn's disease, and ulcerative colitis, and pauchitis are chronic inflammatory conditions, and known for causing disturbed homeostatic balance among the intestinal immune compartment, gut epithelium and microbiome. An increasing trend of IBDs in incidence, prevalence, and severity has been reported during recent years. Probiotic strains have been reported to manage the IBDs and related pathologies, and hence are current hot topics of research for their potential to manage metabolic diseases as well as various immunopathologies. However, the probiotics industry will need to undergo a transformation, with increased focus on stringent manufacturing guidelines and high-quality clinical trials. This article reviews the present state of art of role of probiotic bacteria in reducing inflammation and strengthening the host immune system with reference to the management of IBDs. We infer that t healthcare will move beyond its prevailing focus on human physiology, and embrace the superorganism as a paradigm to understand and ameliorate IBDs.

摘要

多种共生肠道细菌和致病细菌可能参与炎症性肠病(IBD)的发病机制,IBD是一种具有致病背景的慢性疾病,涉及免疫遗传和环境因素。IBD包括克罗恩病、溃疡性结肠炎和袋炎,是慢性炎症性疾病,以破坏肠道免疫区室、肠道上皮和微生物群之间的稳态平衡而闻名。近年来,IBD的发病率、患病率和严重程度呈上升趋势。据报道,益生菌菌株可治疗IBD及相关病症,因此,因其管理代谢性疾病以及各种免疫病症的潜力,目前成为研究的热点话题。然而,益生菌行业需要进行变革,更加注重严格的生产规范和高质量的临床试验。本文参考IBD的管理,综述了益生菌在减轻炎症和增强宿主免疫系统方面的作用的现状。我们推断,医疗保健将超越其目前对人体生理学的关注,将超级生物体作为理解和改善IBD的范例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f978/6709984/652ef9d82b3d/nihms-1000660-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f978/6709984/e8bf9a370b64/nihms-1000660-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f978/6709984/652ef9d82b3d/nihms-1000660-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f978/6709984/e8bf9a370b64/nihms-1000660-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f978/6709984/652ef9d82b3d/nihms-1000660-f0002.jpg

相似文献

1
PROBIOTIC APPROACHES FOR TARGETING INFLAMMATORY BOWEL DISEASE: AN UPDATE ON ADVANCES AND OPPORTUNITIES IN MANAGING THE DISEASE.靶向炎症性肠病的益生菌疗法:疾病管理进展与机遇的最新情况
Int J Probiotics Prebiotics. 2016;11(3-4):99-116.
2
A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration.炎症性肠病综述:微生物、免疫与神经心理整合模型
Public Health Rev. 2021 May 5;42:1603990. doi: 10.3389/phrs.2021.1603990. eCollection 2021.
3
Inflammatory Bowel Sugar Disease: A Pause From New Pharmacological Agents and an Embrace of Natural Therapy.炎症性肠糖病:暂停新药研发,拥抱自然疗法
Cureus. 2023 Aug 1;15(8):e42786. doi: 10.7759/cureus.42786. eCollection 2023 Aug.
4
Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease?益生菌诱导的耐受树突状细胞:炎症性肠病的一种新疗法?
Int J Mol Sci. 2021 Jul 31;22(15):8274. doi: 10.3390/ijms22158274.
5
Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering.炎症性肠病治疗学:专注于益生菌工程。
Mediators Inflamm. 2022 Jan 17;2022:9621668. doi: 10.1155/2022/9621668. eCollection 2022.
6
Time to recognize our fellow travellers.是时候认识一下我们的同行者了。
J Gen Intern Med. 2012 Dec;27(12):1704-6. doi: 10.1007/s11606-012-2105-6. Epub 2012 May 16.
7
Taxonomic and phenotypic analysis of bifidobacteria isolated from IBD patients as potential probiotic strains.从 IBD 患者中分离的双歧杆菌的分类和表型分析作为潜在的益生菌菌株。
BMC Microbiol. 2024 Jun 29;24(1):233. doi: 10.1186/s12866-024-03368-4.
8
The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.炎症、营养供应和共生微生物群在肠道病原体感染中的作用。
Microbiol Spectr. 2015 Jun;3(3). doi: 10.1128/microbiolspec.MBP-0008-2014.
9
Importance of Gut Microbiota in Patients with Inflammatory Bowel Disease.肠道微生物群在炎症性肠病患者中的重要性。
Nutrients. 2024 Jun 30;16(13):2092. doi: 10.3390/nu16132092.
10
Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools.炎症性肠病中的肠道微生物群调节:从旧范式到革命性工具
Int J Mol Sci. 2025 Mar 27;26(7):3059. doi: 10.3390/ijms26073059.

引用本文的文献

1
Prophylactic vs. Therapeutic Effect of Probiotics on the Inflammation Mediated by the NF-κB Pathway in Inflammatory Bowel Conditions.益生菌对炎症性肠病中由NF-κB途径介导的炎症的预防作用与治疗作用
Biomedicines. 2023 Jun 9;11(6):1675. doi: 10.3390/biomedicines11061675.
2
Evaluation of Microbiome Alterations Following Consumption of BIOHM, a Novel Probiotic.评价新型益生菌 BIOHM 对肠道菌群的影响
Curr Issues Mol Biol. 2021 Nov 29;43(3):2135-2146. doi: 10.3390/cimb43030148.
3
Diversion Colitis: Macro and Microscopic Findings after Probiotics Stimulation.

本文引用的文献

1
Probiotic metabolites as epigenetic targets in the prevention of colon cancer.益生菌代谢产物作为预防结肠癌的表观遗传靶点。
Nutr Rev. 2013 Jan;71(1):23-34. doi: 10.1111/j.1753-4887.2012.00542.x. Epub 2012 Nov 9.
2
Metagenomics in animal gastrointestinal ecosystem: a microbiological and biotechnological perspective.动物胃肠道生态系统中的宏基因组学:微生物学和生物技术视角。
Indian J Microbiol. 2008 Jun;48(2):216-27. doi: 10.1007/s12088-008-0027-0. Epub 2008 Jun 17.
3
Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases.
改道性结肠炎:益生菌刺激后的宏观和微观表现
Biology (Basel). 2021 Apr 6;10(4):303. doi: 10.3390/biology10040303.
4
Efficacy of probiotics for managing infantile colic due to their anti-inflammatory properties: a meta-analysis and systematic review.益生菌因其抗炎特性对治疗婴儿腹绞痛的疗效:一项荟萃分析和系统评价
Clin Exp Pediatr. 2021 Dec;64(12):642-651. doi: 10.3345/cep.2020.01676. Epub 2021 Apr 12.
5
Anti-Inflammatory and Gut Microbiota Modulatory Effect of Strain LDTM 7511 in a Dextran Sulfate Sodium-Induced Colitis Murine Model.菌株LDTM 7511在葡聚糖硫酸钠诱导的结肠炎小鼠模型中的抗炎及肠道微生物群调节作用
Microorganisms. 2020 Jun 4;8(6):845. doi: 10.3390/microorganisms8060845.
降低胆固醇的益生菌作为代谢性疾病的潜在生物疗法。
Exp Diabetes Res. 2012;2012:902917. doi: 10.1155/2012/902917. Epub 2012 May 3.
4
Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance.细菌来源的天然抗菌肽:特性及其在对抗抗生素耐药性方面的潜在应用。
J Appl Microbiol. 2012 Oct;113(4):723-36. doi: 10.1111/j.1365-2672.2012.05338.x. Epub 2012 Jun 8.
5
Probiotics, their health benefits and applications for developing healthier foods: a review.益生菌、其健康益处以及在开发更健康食品中的应用:综述。
FEMS Microbiol Lett. 2012 Sep;334(1):1-15. doi: 10.1111/j.1574-6968.2012.02593.x. Epub 2012 May 28.
6
Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer.代谢组学在理解过氧化物酶体增殖物激活受体(PPARs)在糖尿病、肥胖症和癌症中的作用中的应用。
Genome Med. 2012 Apr 30;4(4):32. doi: 10.1186/gm331.
7
Molecular mechanisms of probiotic action: a proteomic perspective.益生菌作用的分子机制:蛋白质组学视角。
Curr Opin Microbiol. 2012 Jun;15(3):390-6. doi: 10.1016/j.mib.2012.03.006. Epub 2012 Apr 24.
8
Early administration of probiotic Lactobacillus acidophilus and/or prebiotic inulin attenuates pathogen-mediated intestinal inflammation and Smad 7 cell signaling.早期给予益生菌嗜酸乳杆菌和/或益生元菊粉可减轻病原体介导的肠道炎症和Smad 7细胞信号传导。
FEMS Immunol Med Microbiol. 2012 Aug;65(3):467-80. doi: 10.1111/j.1574-695X.2012.00978.x. Epub 2012 May 25.
9
Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.益生菌治疗炎症性肠病的管理:成人患者干预研究的系统评价。
Drugs. 2012 Apr 16;72(6):803-23. doi: 10.2165/11632710-000000000-00000.
10
Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases.营养与微生物群在炎症性肠病易感性中的作用。
Mol Nutr Food Res. 2012 Apr;56(4):524-35. doi: 10.1002/mnfr.201100630.